Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

ABSTRACT:

Background

Prostate cancer remains a significant health problem for men in the Western world. Although treatment modalities are available, these do not confer long-term benefit and are accompanied by substantial side effects. Adoptive immunotherapy represents an attractive alternative to conventional treatments as a means to control tumor growth.

Methods

To selectively target the tumor-expressed form of Muc1 we constructed a retroviral vector encoding a chimeric antigen receptor (CAR) directed against the aberrantly-expressed extracellular portion of Muc1 called the 'variable number of tandem repeats'.

Results

We now demonstrate that T cells can be genetically engineered to express a CAR targeting the tumor-associated antigen Muc1. CAR-Muc1 T cells were able to select

SUBMITTER: Sanchez C 

PROVIDER: S-EPMC3883310 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature